



(11)

EP 2 496 244 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73, 74

(51) Int Cl.:
A61K 38/16 ^(2006.01) **A61K 38/17** ^(2006.01)
A61P 35/00 ^(2006.01)

(48) Corrigendum issued on:
08.11.2017 Bulletin 2017/45

(86) International application number:
PCT/US2010/054608

(45) Date of publication and mention
of the grant of the patent:
12.04.2017 Bulletin 2017/15

(87) International publication number:
WO 2011/053750 (05.05.2011 Gazette 2011/18)

(21) Application number: **10827507.4**

(22) Date of filing: **29.10.2010**

(54) **DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER**
WIRKSTOFFRESISTENTE IMMUNTHERAPIE ZUR KREBSBEHANDLUNG
IMMUNOTHÉRAPIE PHARMACORÉSISTANTE POUR LE TRAITEMENT D'UN CANCER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

• **LAMB, Lawrence, S.**
Birmingham, AL 35294 (US)

(30) Priority: **02.11.2009 US 257136 P**

(74) Representative: **Hart, Deborah Mary et al**
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL (GB)

(43) Date of publication of application:
12.09.2012 Bulletin 2012/37

(56) References cited:
US-A- 6 071 512

(60) Divisional application:
17165351.2

(73) Proprietors:
• **Emory University**
Atlanta, Georgia 30322 (US)
• **Children's Healthcare of Atlanta, Inc.**
Atlanta, GA 30329 (US)
• **The UAB Research Foundation**
Birmingham, AL 35294-0107 (US)

• **SCHROEDER MARK A ET AL: "Forced
expression of the IY mutant inosine
monophosphate dehydrogenase II results in
physiologically significant resistance to
mycophenolic acid in vitro", BLOOD, AMERICAN
SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11,
suppl, 1 June 2004 (2004-06-01), XP009171503,
ISSN: 0006-4971**

(72) Inventors:
• **SPENCER, H., Trent**
Marietta
GA 30062 (US)
• **DASGUPTA, Anindya**
Anderson, SC 29625 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 496 244 B8

- STEPHEN R MATTAROLLO ET AL:
"Chemotherapy and zoledronate sensitize solid tumour cells to V[gamma]9V[delta]2 T cell cytotoxicity", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 56, no. 8, 31 January 2007 (2007-01-31), pages 1285-1297, XP019514181, ISSN: 1432-0851, DOI: 10.1007/S00262-007-0279-2
- H T Spencer ET AL: "A gene transfer strategy for making bone marrow cells resistant to trimetrexate", Blood, 1 January 1996 (1996-01-01), pages 2579-2587, XP055073297, Retrieved from the Internet:
URL: <http://bloodjournal.hematologylibrary.org/content/87/6/2579.full.pdf#page=1&view=FitH> [retrieved on 2013-07-29]
- D. W. Mcmillin ET AL: "Complete Regression of Large Solid Tumors Using Engineered Drug-Resistant Hematopoietic Cells and Anti-CD137 Immunotherapy", Human Gene Therapy, 1 August 2006 (2006-08-01), pages 798-806, XP055073317, Retrieved from the Internet:
URL: <http://online.liebertpub.com/doi/pdf/10.1089/hum.2006.17.798> [retrieved on 2013-07-29]
- RUPAL RAMAKRISHNAN ET AL: "Combined modality immunotherapy and chemotherapy: a new perspective", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 10, 17 May 2008 (2008-05-17), pages 1523-1529, XP019624425, ISSN: 1432-0851
- DOTTI G ET AL: "CURRENT STATUS OF GENETIC MODIFICATION OF T CELLS FOR CANCER TREATMENT", CYTOTHERAPY, ISIS MEDICAL MEDIA, OXFORD, GB, vol. 7, no. 3, 1 July 2005 (2005-07-01), pages 262-272, XP009060587, ISSN: 1465-3249, DOI: 10.1080/14653240510027217
- CHINNASAMY DHANALAKSHMI ET AL:
"Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide", HUMAN GENE THERAPY, vol. 15, no. 8, August 2004 (2004-08), pages 758-769, XP055073341, ISSN: 1043-0342
- J. Jiang ET AL: "Treatment of Advanced Gastric Cancer by Chemotherapy Combined with Autologous Cytokine-induced Killer Cells", Anticancer Research, 1 January 2006 (2006-01-01), pages 2237-2242, XP055074346, Retrieved from the Internet:
URL: <http://ar.iiarjournals.org/content/26/3B/2237.full.pdf#page=1&view=FitH> [retrieved on 2013-08-06]
- DASGUPTA A. ET AL: 'Engineered drug resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge' BIOCHEM. BIOPHYS. RES. COMMUN. vol. 391, no. 1, 01 January 2010, pages 170 - 175, XP008156422
- NOWAK A.K. ET AL: 'Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors' CANCER RESEARCH vol. 63, 01 August 2003, pages 4490 - 4496, XP008156419
- HERMANS I.F. ET AL: 'Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model' CANCER RESEARCH vol. 63, 01 December 2003, pages 8408 - 8413, XP008156423
- HEIMBERGER A.B. ET AL: 'Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study' NEURO-ONCOLOGY vol. 10, 13 December 2008, pages 98 - 103, XP008156428